KYMAB
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. The company was founded in 2010 and is based in Cambridge, the United Kingdom.
KYMAB
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2010-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.kymab.com
Total Employee:
101+
Status:
Active
Contact:
44 1223 833301
Email Addresses:
[email protected]
Total Funding:
229.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Mobile Non Scaleable Content
Similar Organizations
Adamis Pharmaceuticals
Adamis Pharmaceuticals is a biopharmaceutical company developing therapeutics for respiratory diseases and cancer.
CureVac
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Innovent Biologics
Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.
Nautilus Biotech
Nautilus Biotech is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Current Employees Featured
Founder
Investors List
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Grant - Kymab
Malin Corporation
Malin Corporation investment in Series C - Kymab
Woodford Investment Management
Woodford Investment Management investment in Series C - Kymab
Wellcome Trust
Wellcome Trust investment in Series C - Kymab
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Series C - Kymab
Hepalink
Hepalink investment in Series C - Kymab
ORI Capital
ORI Capital investment in Series C - Kymab
Malin Corporation
Malin Corporation investment in Series B - Kymab
Woodford Investment Management
Woodford Investment Management investment in Series B - Kymab
Wellcome Trust
Wellcome Trust investment in Series B - Kymab
Official Site Inspections
http://www.kymab.com Semrush global rank: 3.64 M Semrush visits lastest month: 3.91 K
- Host name: 178.62.11.133
- IP address: 178.62.11.133
- Location: London United Kingdom
- Latitude: 51.5353
- Longitude: -0.6658
- Timezone: Europe/London
- Postal: SL1
